TABLE 1.
Study characteristics of the 77 studies included in the qualitative synthesis
| Study characteristicc | Value (no. [%]) (n = 77) |
|---|---|
| TB burden of country of enrollmenta | |
| Low (<10 cases per 100,000 population per yr) | 2 (2.60) |
| Middle (11 to 40 cases per 100,000 population per yr) | 8 (10.39) |
| High (>40 cases per 100,000 population per yr and/or WHO list of 30 highest burden countries) | 64 (83.12) |
| Multisiteb | 3 (3.90) |
| Persons with drug resistance at baseline included | |
| Yes | 20 (25.97) |
| No | 20 (25.97) |
| Unclear/not reported | 37 (48.05) |
| Persons with a history of prior TB included | |
| Yes | 17 (22.08) |
| No | 21 (27.27) |
| Unclear/not reported | 39 (50.65) |
| Persons with BCG vaccination included | |
| Yes | 9 (11.69) |
| Unclear/Not reported | 68 (88.31) |
| Persons living with HIV included | |
| Yes | 19 (24.68) |
| No | 45 (58.44) |
| Unclear/not reported | 13 (16.88) |
a
Based on 2019 data.
b
Three studies recruited participants from different countries with different TB burden status.
c
TB, tuberculosis; WHO, World Health Organization; BCG, Bacillus Calmette-Guérin.